Business Wire

CA-PROSIMO

12.6.2024 16:01:30 CEST | Business Wire | Press release

Share
Prosimo and Palo Alto Networks bring Zero Trust to Application Workloads in Multi Cloud Environments

Prosimo, a leader in multi cloud networking software [MCNS], today announced an integration with Palo Alto Networks for a powerful new approach to security that protects applications and workloads in multi cloud environments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612713674/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hop by Hop Traceability Including the Packets Being Actioned Within a Firewall (Graphic: Business Wire)

With Prosimo’s Full Stack Cloud Transit platform, customers can seamlessly integrate with Palo Alto Networks VM-Series Virtual Next-Generation Firewall (NGFW), allowing enterprises to deploy security as close as possible to the workloads they protect. This architecture greatly reduces the time and effort required to secure application access across multi cloud environments for users and workloads.

“Together with Palo Alto Networks VM-Series virtual firewalls, we’re providing organizations with a Zero Trust framework so they can be confident their application workloads are secure while ensuring fast and reliable connectivity to and across cloud providers,” said Prosimo Vice President of Product Mani Ganesan. “This integration allows enterprises to improve observability, increase operational efficiency, and safely gives them more control of their cloud environment.”

Join the Office Hours to explore the use case and see a live demo here.

Most integrations today focus on orchestrating firewalls and inserting them in the path of cloud network traffic, where they rely on IP addresses/port numbers to redirect traffic. Prosimo instead provides service insertion policies that allow users to define sophisticated rules that determine which traffic will be routed for advanced inspection to the firewall.

Prosimo simplifies deployment for two flexible architectures for Palo Alto Networks VM-Series virtual firewalls:

  • Centralized: VM-Series virtual firewall is deployed into a centralized VPC for east-west (VPC-to-VPC) or north-south (Internet egress and ingress, cloud to on-premises) traffic. This is the most common Prosimo model and provides security control and ongoing manageability.
  • Distributed: VM-Series virtual firewalls are deployed in each virtual private cloud. This method is typically used in cases where VPCs need to be isolated and require local ingress or egress.

“Speed is critical in the cloud, so the speed of operations in configuring software firewalls, like the VM-Series virtual firewall, needs to match the speed of cloud deployments,” said Vitaliy Sivetskiy, senior product manager of Palo Alto Networks. “Integrating Prosimo’s Full Stack Cloud Transit and Palo Alto Networks VM-Series virtual firewall makes network security teams' lives easier. Our single intuitive operating model for connectivity and virtual firewall insertion means customers have more time to focus on application business innovation versus managing network and security infrastructure. This enables organizations to help protect all clouds, the right way, with agility.”

Link to Solution Brief

Providing Multi-Layer Security to Navigate Cloud Firewall Complexity

While a well-constructed multi cloud networking architecture can enhance security, scaling of firewalls can be complex. Common challenges include ensuring the virtual firewall can handle the required elasticity associated with growing cloud resources, managing complex network configurations for auto scaling, and implementing ongoing route updates to direct traffic through the next-generation firewall while maintaining segmentation and isolation.

Integrating Prosimo with Palo Alto Networks VM-Series virtual firewalls ensures enhanced security and scalability across the network and application layer. Palo Alto Networks Next-Generation Firewalls offer comprehensive Layer 7 inspection, while Prosimo stands out as a leading provider in the MCNS market capable of delivering network segmentation spanning Layer 3 to Layer 7.

With native integration, customers can provision new virtual firewalls in a few clicks. From a single dashboard, users can manage the lifecycle of those firewalls, quickly scaling up or down while segmenting the necessary subnets and corresponding cloud-native elements.

Customers can see immediate benefits from the integration through:

  • Migrating to Palo Alto Networks software next-generation firewalls faster, eliminating blind spots for both network and security teams.
  • Right-sizing software firewalls to optimize cloud costs.
  • Using the existing firewall investment to segment east-west and north-south data movement within clouds.

Go to prosimo.io to learn how Prosimo and Palo Alto Networks enable enterprises to build, modernize, and future-proof cloud infrastructure.

About Prosimo

Prosimo delivers a simplified multicloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have successfully adopted Prosimo to roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst, WRVI Capital, and Blackrock. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240612713674/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye